We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Newly-Launched Portable Molecular Diagnostic Platform Detects COVID-19 at Point-of-Care within 30 Minutes

By LabMedica International staff writers
Posted on 15 Oct 2021
Print article
Image: The PEBBLE qcLAMP Platform (Photo courtesy of BIOPIX-T)
Image: The PEBBLE qcLAMP Platform (Photo courtesy of BIOPIX-T)

A new portable molecular diagnostic platform and its compatible diagnostic test for the detection of SARS-CoV-2 delivers results within 30 minutes at the Point-of-Care (POC).

BIOPIX-T (Voutes, Greece) has launched its portable molecular diagnostic platform, the PEBBLE qcLAMP Platform, along with its compatible diagnostic test for the detection of the SARS-CoV-2 virus. PEBBLE is the first Greek portable molecular diagnostic device based on LAMP technology (Isothermal PCR), which can be used at the POC. PEBBLE as well as COV19 qcLAMP kit, the corresponding diagnostic kit to be used together with the diagnostic instrument for the detection of SARS-CoV-2, are now CE Marked.

The reliability of the PEBBLE device is comparable to the corresponding laboratory ‘reference devices’, which cost nevertheless tens of times more and cannot be transported to the points of interest. This offers to the responsible authorities an excellent new weapon for management of the pandemic as they will be able to perform rapid (within 30 minutes) and much more reliable molecular tests at a cost comparable to that of rapid tests. Other innovative features of the device are expected to be gradually certified and utilized, such as the ability to perform tests on a saliva sample, without the unpleasant current sampling procedure.

“BIOPIX-T’s innovative molecular diagnostic device can be a catalyst, giving a very fast, cost-effective and at the same time reliable result to all points of care as well as other points of interest, such as airports, cruise ships, companies, community services, but also hotels, border entry points or immigration hot-spots, etc.,” said George Papadakis who leads BIOPIX-T.

Related Links:
BIOPIX-T

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
SARS-CoV-2 Test
One Step SARS-CoV-2 Nucleic Acid Detection Kit (P761H)

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more